Drug Delivery Through Blood Brain Barrier: Taming the Bottleneck in CNS Therapeutics
Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. Bioassays. 1993; 15:341–6. https:// doi.org/10.1002/bies.950150508 PMid:8102053
Brightman MW, Zis K, Anders J. Morphology of cerebral endothelium and astrocytes as determinants of the neuronal microenvironment. In: Hossmann KA, Klatzo I, editors. Cerebrovascular transport mechanisms. Acta Neuropathologica Supplementum. Berlin: Springer; 1983. p. 21–33. https://doi.org/10.1007/978-3-642-68970-3_2 PMid:6346778
Martin B, Robert L, Henry B, Mathiowitz E. Encyclopedia of controlled drug delivery, Vol. l, New York: John Wiley and Sons Inc; l999. p. 184-210.
Pankajavalli R. The role of P-glycoprotein in the bloodbrain barrier. Einstein Quart J Biol Med. 2003; 19:160–5.
Dwibhashyam VS, Nagappa AN. Strategies for enhanced drug delivery to the central nervous system. IJPS. 2008; 70(2):145–53. https://doi.org/10.4103/0250-474X.41446 PMid:20046703 PMCid:PMC2792490
Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int. J Nanomedicine. 2014; 9:2241– 57. https://doi.org/10.2147/IJN.S61288 PMid:24872687 PMCid:PMC4026551
Bodor N. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science. l992; 257:1698–700.
Smith QR. Carrier-mediated transport to enhance drug delivery to brain. International Congress Series. 2005; 1277:63–74. https://doi.org/10.1016/j.ics.2005.02.012
Kang YS, Bickel U, Pardridge WM. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab Dispos. 1994; 22(1):99– 105.PMid:8149897
Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2012; 64:686–700. https://doi.org/10.1016/j.addr.2011.10.007 PMid:22100125
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001; 47:65–81. https://doi.org/10.1016/S0169-409X(00)00122-8
Scheld WM. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis. 1989; 11 Suppl 7:S1669–90. https://doi.org/10.1093/clinids/11.Supplement_7.S1669 PMid:2690302
Rapoport SI, Robinson PJ. Tight-junctional modification as the basis of osmotic opening of the blood–brain barrier. Ann N Y Acad Sci. 1986; 481:250–67. https://doi.org/10.1111/j.1749-6632.1986.tb27155.x
Cloughesy TF, Black KL. Pharmacological blood–brain barrier modification for selective drug delivery. J Neurooncol. 1995; 26:125–32. https://doi.org/10.1007/BF01060218
Cho CW, Lin Y, Cobb WN. Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain micro vessel endothelial cells. Pharm Res. 2002; 115:413–24.
Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998; 5:415–41. https://doi.org/10.3109/10611869808997870 PMid:9783675
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.